MOTS-c's 7–5 Vote: The Mitochondrial Peptide's Narrow Path Forward
Of the four peptides recommended on day one of the July 2026 PCAC meeting, MOTS-c had the shakiest passage: 7–5 with two abstentions, the only day-one compound that could not muster eight yes votes. It is also, scientifically, the most unusual thing the committee looked at — a peptide encoded not in the nuclear genome but in mitochondrial DNA, and one your own body upregulates when you exercise.
What Makes MOTS-c Different
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide expressed from a short open reading frame inside the mitochondrial genome. Research interest centers on its role in metabolic homeostasis: rodent and early human data associate it with improved insulin sensitivity, fat oxidation, and exercise capacity, which is why it is frequently described as an "exercise mimetic" in the literature. Exercise itself raises endogenous MOTS-c levels — a detail with real protocol implications for the performance community, which PowerPeptides covers from the training angle.
What the FDA Evaluated
The proposed uses before the committee were obesity and osteoporosis. FDA staff applied the same critique they applied everywhere: human trials too small and short to establish safety or effectiveness, and inadequate chemical characterization of what is actually being sold as MOTS-c. Staff recommended against listing. The committee disagreed — but with visibly less conviction than it showed for BPC-157, KPV, and TB-500. Two members abstained rather than take a side.
Why the Softer Vote?
- Obesity is not an access desert. The 2026 obesity-treatment landscape includes multiple approved GLP-1 and incretin drugs, an approved oral option, and aggressive price competition. The harm-reduction argument — people have no sanctioned option, so compounding beats the gray market — is weakest where sanctioned options are abundant.
- Mechanistic novelty cuts both ways. A mitochondrial-derived peptide with systemic metabolic effects is fascinating and genuinely underexplored — which is exactly the profile that makes cautious reviewers hesitant to green-light patient-specific compounding.
Practical Status
MOTS-c joins the rulemaking queue with the other five recommended peptides. Nothing is legal to compound today; the realistic path to a 503A listing runs 12–24 months of rulemaking if the FDA acts, against a historical precedent (glutathione, recommended 2022, still unlisted) that says it may not. Research-grade availability is unchanged.
For the underlying science — the mitochondrial biology, the exercise-upregulation data, and the honest state of the human evidence — see our full MOTS-c profile.
Third-party tested research peptides with published COAs. Use code POWER at checkout.
Code: POWERView Catalog →US-based research supplier, batch-tested catalog. Use code POWER at checkout.
Code: POWERView Catalog →We may earn a commission from links above at no cost to you. All compounds are for laboratory research use only.
Frequently Asked Questions
MOTS-c was recommended 7-5 with two abstentions on July 23, 2026 - the narrowest approval of the meeting's first day.
Obesity and osteoporosis.
A 16-amino-acid peptide encoded in mitochondrial DNA, studied for metabolic effects including insulin sensitivity and exercise capacity. Exercise itself raises endogenous MOTS-c levels.
No. Like the other recommended peptides, it awaits FDA review and potential rulemaking expected to run 12 to 24 months if it proceeds.
Committee hesitation likely reflected the crowded approved-treatment landscape for obesity and the compound's mechanistic novelty; two members abstained rather than vote either way.